36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos clínicos más relevantes

The San Antonio Breast Cancer Symposium, in which breast cancer management is updated from a multidisciplinary perspective, is considered the most important international meeting on breast cancer. Notable contributions this year included 10-year studies of adjuvant tamoxifen and a phase ii trial of letrozole with PD 0332991, a cyclin-dependent kinase 4/6 inhibitor. The present article summarizes, under distinct subheadings, the contributions with greatest clinical impact.